Role of Antiplatelet Therapy in Stroke Prevention in Patients With Atrial Fibrillation.
J Am Osteopath Assoc
; 117(12): 761-771, 2017 Dec 01.
Article
em En
| MEDLINE
| ID: mdl-29181519
ABSTRACT
Patients with atrial fibrillation are at increased risk of having a cardioembolic stroke. The use of oral anticoagulation is now well established to prevent strokes in patients with atrial fibrillation and a CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75 years [2 points], diabetes mellitus, prior stroke/transient ischemic attack or thromboembolism [2 points], vascular disease, age 65 to 74 years, and sex category) score of greater than 1, beyond sex. However, the role of antiplatelet therapy, specifically aspirin in low-risk patients or as an alternative to oral anticoagulation, remains controversial. The most recent US guidelines conflict with the European guidelines, which do not recommend antiplatelet monotherapy for stroke prevention irrespective of stroke risk. The aim of this review is to summarize published studies that question the role of aspirin in preventing strokes associated with atrial fibrillation. Overall, aspirin is found to play a limited role in the prevention of stroke in patients with atrial fibrillation and is associated with a similar risk of hemorrhagic events compared with anticoagulants. The benefit of dual antiplatelet therapy as an alternative to oral anticoagulation requires further study.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Fibrilação Atrial
/
Inibidores da Agregação Plaquetária
/
Aspirina
/
Acidente Vascular Cerebral
/
Anticoagulantes
Tipo de estudo:
Etiology_studies
/
Guideline
Limite:
Aged
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
J Am Osteopath Assoc
Ano de publicação:
2017
Tipo de documento:
Article